MTOR and cancer: Previous reports of synergistic anti-cancer effects of HDACi with PI3K/mTOR pathway inhibitors have identified distinct mechanisms of tumor cell killing among different blood cancers [32, 55-58], further supporting the idea that the mechanisms of synergy are context-dependent.